Vanguard Asset Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
Other funds holding CTMX
KCM
Vanguard Asset Management's CTMX Position: Q3 2026 in Review
Vanguard Asset Management held its CytomX Therapeutics (CTMX) position steady in Q3 2026 at 122,893 shares worth $334K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.
Vanguard Asset Management first reported a position in CTMX in Q1 2026 and has held it in 3 quarters since. The position peaked at $578K in Q1 2026. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.
- Vanguard Asset Management held 122,893 shares of CytomX Therapeutics worth $334K as of Q3 2026.
- Vanguard Asset Management left its CytomX Therapeutics share count unchanged in Q3 2026.
- CytomX Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #2310 holding.
- Vanguard Asset Management first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Asset Management's CytomX Therapeutics position peaked at $578K in Q1 2026.
- 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.